VZL 2006, 75(1):7-12

Cardiac Complications during Oncologic Treatment - Current Diagnostic Methods

Jan M. Horáček ORCID...1,2, Radek Pudil3, Ladislav Jebavý1,2, Miloš Tichý1, Jana Pástorová4, Ladislav Slováček1,2, Miroslav Brndiar1
1 Univerzita obrany, katedra válečného vnitřního lékařství Fakulty vojenského zdravotnictví, Hradec Králové
2 Oddělení klinické hematologie II. interní kliniky Fakultní nemocnice a Lékařské fakulty UK v Hradci Králové
3 I. interní klinika Fakultní nemocnice a Lékařské fakulty UK v Hradci Králové
4 Klinika gerontologická a metabolická Fakultní nemocnice a Lékařské fakulty UK v Hradci Králové

Článek se zabývá problematikou kardiotoxicity protinádorové léčby. V první časti je stručně pojednáno o nejčastějších příčinách a projevech kardiotoxicity při léčbě onkologických pacientů. V druhé části je uveden přehled současných diagnostických možností kardiotoxicity se zaměřením na biochemické markery srdečního poškození. Jsou prezentovány i vlastní výsledky autorů. Součástí článku je přehledná tabulka ukazující současnou klasifikaci kardiotoxicity podle Světové zdravotnické organizace (WHO).

Keywords: Kardiotoxicita; Onkologická léčba; Diagnostika; Kardiomarkery; NT-proBNP

The article deals with problems of cardiotoxicity of antitumorous treatment. In the first part, the most frequent causes and signs of cardiotoxicity of oncologic treatment are briefly mentioned. In the second part, the present-day diagnostic methods of cardiotoxicity are reviewed. The role of potential biochemical markers of heart damage is emphasized. The authors' own results are also presented. The article contains a table showing the current classification of cardiotoxicity according to the World Health Organization (WHO).

Keywords: Cardiotoxicity; Oncology treatment; Diagnostics; Cardiomarkers; NT-proBNP

Received: November 14, 2005; Published: March 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horáček, J.M., Pudil, R., Jebavý, L., Tichý, M., Pástorová, J., Slováček, L., & Brndiar, M. (2006). Cardiac Complications during Oncologic Treatment - Current Diagnostic Methods. Vojenské Zdravotnické Listy, 75(1), 7-12
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. ADAMCOVA, M. - STERBA, M. - SIMUNEK, T., et al. Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert. Opin. Drug Saf., 2005, vol. 4, p. 457-472. Go to original source... Go to PubMed...
    2. ASCHERMANN, M., et al. Kardiologie. 1. vyd. Praha, Galén, 2004. 1481 s.
    3. AUNER, HW. - TINCHON, C. - LINKESCH, W., et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann. Hematol., 2003, vol. 82, p. 218-222. Go to original source... Go to PubMed...
    4. BAUCH, M. - ESTER, A. - KIMURA, B., et al. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer, 1992, vol. 69, p. 1492-1497. Go to original source...
    5. CARDINALE, D. - SANDRI, MT. - COLOMBO, A., et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation, 2004, vol. 109, p. 2749-2754. Go to original source... Go to PubMed...
    6. COWIE, MR. - JOURDAIN, P. - MAISEL, A., et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur. Heart J., 2003, vol. 24, p. 1710-1718. Go to original source... Go to PubMed...
    7. ELBL, L., et al. Poškození srdce protinádorovou léčbou. 1. vyd. Praha, Grada Publishing, 2002. 156 s.
    8. DAVIS, MJ. - ROWLEY, DS. - BRAINE, HG., et al. Clinical toxicity of cryopreserved bone marrow graft infusion. Blood, 1990, vol. 75, p. 781-786. Go to original source...
    9. EWER, MS. - BENJAMIN, RS. Cardiac complications. In HOLLAND, JF. Cancer Medicine. Philadelphia, Lea and Febiger, 1993, p. 2332-2348.
    10. FINK, FM. - GENSER, N. - FINK, C., et al. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med. Pediatr. Oncol., 1995, vol. 25, p. 185-189. Go to original source... Go to PubMed...
    11. GANZ, WI. - SRIDHAR, KS. - GANZ, SS., et al. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology, 1996, vol. 53, p. 461-470. Go to original source... Go to PubMed...
    12. GOLDENBERG, MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther., 1999, vol. 21, p. 309-318. Go to original source... Go to PubMed...
    13. HORÁČEK, JM. - PUDIL, R. - JEBAVÝ, L., et al. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma, 2005, vol. 52, p. 430-434. Go to PubMed...
    14. HORACEK, JM. - PUDIL, R. - TICHY, M., et al. Monitoring of cardiotoxicity during haematopoietic stem cell transplantation in acute leukemia. Haematologica/Hematol. J., 2005, vol. 90 (Suppl 2), p. 199-200.
    15. KEUNG, YK. - LAU, S. - ELKAYAM, U., et al. Cardiac arrhythmia after infusion of cryopreserved stem cells. Bone Marrow Transplant., 1994, vol. 14, p. 363-367. Go to PubMed...
    16. KILICKAP, S. - BARISTA, I. - AKGUL, E., et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann. Oncol., 2005, vol. 16, p. 798-804. Go to original source... Go to PubMed...
    17. KISMET, E. -VARAN, A. - AYABAKAN, C., et al. Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr. Blood Cancer, 2004, vol. 42, p. 220-224. Go to original source... Go to PubMed...
    18. MEINARDI, MT. - VAN DER GRAAF, WTA. - VAN VELDHUISEN, DJ., et al. Detection of anthracycline-induced cardiotoxicity. Cancer Treat. Rev., 1999, vol. 25, p. 237-247. Go to original source... Go to PubMed...
    19. NIWA, N. - WATANABE, E. - HAMAGUCHI, M., et al. Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation. Ann. Hematol., 2001, vol. 80, p. 460-465. Go to original source... Go to PubMed...
    20. NOUSIAINEN, T. - JANTUNEN, E. - VANNINEN, E., et al. Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Eur. J. Haematol., 1998, vol. 61, p. 347-353. Go to original source... Go to PubMed...
    21. OKUMURA, H. - IUCHI, K. - YOSHIDA, T., et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol., 2000, vol. 104, p. 158-163. Go to original source... Go to PubMed...
    22. PETERSEN, FB. - BEARMAN, SI. Preparative regimens and their toxicity. In FORMAN, SJ. - BLUME, KG. - THOMAS, ED. Bone marrow transplantation. Boston, Blackwell Scientific Publications, 1994, p. 79-83.
    23. REMME, WJ. - SWEDBERG, K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J., 2001, vol. 22, p. 1527-1560. Go to original source... Go to PubMed...
    24. SANDRI, MT. - SALVATICI, M. - CARDINALE, D., et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin. Chem., 2005, vol. 51, p. 1405-1410. Go to original source... Go to PubMed...
    25. SHAN, K. - LINCOFF, AM. - YOUNG, JB. Anthracycline-induced cardiotoxicity. Ann. Intern. Med., 1996, vol. 125, p. 47-58. Go to original source... Go to PubMed...
    26. SCHLAFER, M. - KAROW, AM. Pharmacological effects of dimethylsulfoxide on the mammalian myocardium. Ann. N. Y. Acad. Sci., 1975, vol. 243, p. 110-121. Go to original source... Go to PubMed...
    27. SNOWDEN, JA. - HILL, GR. - HUNT, P., et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant., 2000, vol. 26, p. 309-313. Go to original source... Go to PubMed...
    28. SPARANO, JA. - BROWN, DL. - WOLFF, AC. Predicting cancer therapy-induced cardiotoxicity. The role of troponins and other markers. Drug Saf., 2002, vol. 25, p. 301-311. Go to original source... Go to PubMed...
    29. SPEYER, JL. - WASSERHEIT, C. Strategies for reduction of anthracycline cardiotoxicity. Semin. Oncol., 1998, vol. 25, p. 525-537.
    30. SUZUKI, T. - HAYASHI, D. - YAMAZAKI, T., et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am. Heart J., 1998, vol. 136, p. 362-363. Go to original source... Go to PubMed...
    31. VON HOFF, DD. - LAYARD, WM. - BASA, P., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med., 1979, vol. 91, p. 710-717. Go to original source... Go to PubMed...
    32. YASUE, H. - YOSHIMURA, M. - SUMIDA, H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation, 1994, vol. 90, p. 195-203. Go to original source... Go to PubMed...
    33. YEH, ET. - TONG, AT. - LENIHAN, DJ. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis and management. Circulation, 2004, vol. 109, p. 3122-3131. Go to original source... Go to PubMed...

    Return to the content